Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data

Dominique Ingram; Ayedh K Alamri; Brittany A Penn; Jennalyn D Mayeux; Christy L Ma; Katharine R Clapham; Anu E Abraham; Dana Klanderud; Ben Sadeh; Emily M Beck; Nathan D Hatton; John J Ryan

doi:10.7759/cureus.31764

Characteristics of Patients With Pulmonary Arterial Hypertension in a Pulmonary Hypertension Association-Accredited Comprehensive Care Center: A Contrast in Features When Compared With US National Registry Data

Cureus. 2022 Nov 21;14(11):e31764. doi: 10.7759/cureus.31764. eCollection 2022 Nov.

Authors

Affiliations

¹ Cardiovascular Medicine, University of Utah, Salt Lake City, USA.
² Department of Medicine, College of Medicine, Northern Border University, Arar, SAU.
³ Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, USA.
⁴ Cardiovascular Medicine, University of Utah, Salt Lake City, UT, USA.
⁵ Pulmonary and Critical Care Medicine, George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, USA.

Abstract

Background Since the initial description in the 1980s, our understanding of the diversity of pulmonary arterial hypertension (PAH) has continued to evolve. In this study, we report the characteristics of patients seen in an academic medical center for PAH from August 2020 through November 2021 and contrast those with nationally reported data from the United States Pulmonary Hypertension Scientific Registry (USPHSR). Study Design Investigators at the University of Utah Pulmonary Hypertension Program prospectively enrolled adult patients diagnosed with WHO Group 1 PAH, who were evaluated between August 2020 and November 2021 in a program-specific registry. Patient exposure and health histories were collected through structured interviews and questionnaires, along with clinical data and medication use. A total of 242 patients were enrolled in the University of Utah Pulmonary Hypertension Registry (UUPHR). Results Of the 242 enrolled patients, the most common etiology was associated PAH (APAH), accounting for 71.1% of the population. The second largest etiology was idiopathic PAH (IPAH) at 26.4%. The remaining patients were distributed between familial PAH (FPAH), pulmonary veno-occlusive disease (PVOD), and others. Of the total population classified as APAH, 39% of cases were noted as secondary to connective tissue disease (CTD) and 33% as toxin-induced. These represented 28% and 24% of the total population, respectively. Conclusions In this US-based accredited academic medical center, the etiology of PAH in our patient population contrasts with national registry data. In the UUPHR, APAH, specifically CTD-PAH and toxin-associated PAH, accounts for the majority of patients with PAH. This contrasts with IPAH, which nationally is the most reported cause of PAH. Differences in our population may reflect the regional variation of the referral site, but it is noteworthy for its contrast with historically reported phenotypes.

Keywords: connective tissue disorder (ctd); idiopathic pulmonary arterial hypertension; methamphetamine induced pulmonary hypertension; s: epidemiology; – pulmonary hypertension.